Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth.
Vascular endothelial growth factor receptor 2 (VEGFR2/KDR) plays a crucial role in tumor-associated angiogenesis and vascularization. It has been established that monoclonal antibodies against VEGFR2 can inhibit angiogenesis. In this study, two naturally processed CD8 T-cell epitopes (VILTNPISM and FSNSTNDILI) were identified from murine KDR. Cytotoxic T lymphocytes targeting endothelial cells could be directly monitored by KDR2 and KDR3 Elispots or major histocompatibility complex class I tetramer staining. Immunization with these two peptides effectively reduced angiogenesis and inhibited tumor growth in mouse models. Thus, vaccination with KDR peptides alone or in combination with other anti-angiogenesis agents may afford a novel immunotherapy for inhibition of tumor growth.
Dong
Yujun
Y
The Vaccine Branch, The Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20889, USA.
Qian
Jiahua
J
Ibrahim
Ramy
R
Berzofsky
Jay A
JA
Khleif
Samir N
SN
D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D002460:Cell Line; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D006183:H-2 Antigens / Q000276:immunology*; D064532:Histocompatibility Antigen H-2D; D007150:Immunohistochemistry; D051379:Mice; D009369:Neoplasms / Q000276:immunology*; D009389:Neovascularization, Pathologic / Q000276:immunology*; D010455:Peptides / Q000276:immunology / Q000627:therapeutic use; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000276:immunology*
D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D006183:H-2 Antigens; D064532:Histocompatibility Antigen H-2D; D010455:Peptides; D040301:Vascular Endothelial Growth Factor Receptor-2